Here are the Form 4 insider transactions from Harvard Apprats REG TCH (HRGN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HRGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HRGN filings page.
Harvard Apparatus Regenerative Technology, Inc. CEO He Junli reported purchasing 361,905 common shares in the September 11, 2026 private placement for $380,000, or $1.05 per share, and converting bridge notes into 683,725 shares at $1.05 per share. The notes represented $717,911 of outstanding principal and accrued interest and were canceled in full. He also purchased 6,725 shares in multiple transactions from September 15 to September 23, 2026, at a weighted average price of $2.15 per share. No Rule 10b5-1 plan is reported.
Harvard Apparatus Regenerative Technology, Inc. granted CEO and director Junli He a nonqualified stock option covering 1,200,000 shares of common stock at an exercise price of $1.09 per share, expiring on July 21, 2036. The award consists of a 600,000-share time-based tranche and a 600,000-share performance-based tranche with distinct vesting conditions.
The time-based portion includes 100,000 shares vesting upon signing of the award agreement, then 16,667 shares vesting monthly from September 1, 2026 until a total of 600,000 shares vest, all subject to continued employment. The performance-based portion vests in four milestone tranches tied to a controlling-stake sale or national exchange listing, share-price performance, additional capital raising of at least $10,000,000, and other conditions, and becomes fully vested upon a Sale Event or Change of Control under the company’s equity plan.
Harvard Apparatus Regenerative Technology, Inc. reported an insider share purchase by its CEO. The company’s Chief Executive Officer and Director, based on this filing, bought 3,000 shares of common stock on 11/25/2025 in an open-market transaction coded “P” for a purchase. The weighted average purchase price reported was $1.70 per share, reflecting multiple trades between November 25 and November 26. Following this transaction, the reporting person beneficially owned 280,575 shares of Harvard Apparatus Regenerative Technology common stock held directly.